I'm currently bullish on Novartis. Despite Goldman Sachs' warning, I think the recent rally is sustainable and the stock is positioned well with a nice yield. I expect it to continue its upward trend, making it a solid choice for a swing trade.

Given the expected growth in the respiratory drugs market driven by increasing prevalence of respiratory disorders and Novartis' strong presence in this space, I anticipate a short-term uptick in NVS stock. A bullish play on NVS seems warranted.

Given the strong growth projections in both the targeted therapeutics and organ transplant markets, NVS is well-positioned to capitalize on these trends, likely resulting in an upward movement in the stock price in the short term. To leverage this potential, we are buying NVS call options instead of shares.

Given the strong growth projections in both the targeted therapeutics and organ transplant markets, NVS is well-positioned to capitalize on these trends, likely resulting in an upward movement in the stock price in the short term.